The Decision That Set Greater Manchester Apart
When nearly every health region in England signed up to the NHS Federated Data Platform, one area chose a different path. Greater Manchester Integrated Care Board, serving roughly 2.8 million residents, became the only ICB in England to decline participation. That choice was not made lightly, and it has not changed despite pressure from central authorities. Understanding why this region continues to hold firm reveals deeper tensions around privacy, procurement, and public trust in digital health initiatives.
The greater manchester data platform debate started in 2023 when NHS England awarded a seven-year contract worth £330 million to Palantir, a US-based technology company known for its work with intelligence agencies. From the beginning, concerns surfaced about the deal’s transparency and the company’s access to sensitive patient information. Greater Manchester’s ICB deferred its decision last year, and in May 2025, a board meeting confirmed that NHS England had not sufficiently addressed the region’s worries.
Reason 1: Palantir’s Reputation and Data Access Policies
Palantir did not arrive in the NHS through a conventional competitive tender. During the pandemic, the company received £60 million without any open competition to build a data platform for tracking COVID-19 patients. That emergency contract eventually evolved into the Federated Data Platform, raising questions about whether the procurement process was fair or thorough. For Greater Manchester’s ICB, this history matters deeply.
What Palantir Staff Can Actually See
NHS England confirmed that Palantir employees could access patient data following a policy change. That revelation provoked outrage among privacy advocates and members of the public alike. The idea that staff from a company with strong ties to US intelligence agencies might view personal health records strikes many as a step too far. In Greater Manchester, this concern amplified existing doubts about the platform’s governance.
Imagine a resident of Salford discovering that their hospital visit data could be reviewed by a private company’s engineers. No explicit consent was sought. No clear opt-out mechanism was widely publicized. For many, that scenario feels like a violation of the confidential relationship they expect with their doctors. The greater manchester data platform alternative, which relies on locally managed systems, avoids this problem entirely.
Political Positions and Public Trust
Palantir’s leadership has taken a series of outspoken political stances over the years, including public positions that many in the UK find controversial. While a company’s politics should not necessarily disqualify it from public contracts, the combination of political activism and access to sensitive health data creates a discomfort that Greater Manchester’s ICB could not ignore. Trust, once damaged, is difficult to rebuild.
Reason 2: No Compelling Evidence That the Platform Delivers Real Benefits
The board meeting in May 2025 highlighted a critical gap: NHS England had not provided convincing proof that the Federated Data Platform actually improves patient outcomes. The system is designed to improve information flow between NHS organizations and reduce the backlog in elective care, which surged during the pandemic. But whether it achieves those goals remains unclear.
The Evidence Gap
When a health region considers adopting a major new technology, it expects to see pilot results, comparative studies, or at minimum, credible projections. Greater Manchester’s ICB reported that “there does not appear to be any compelling evidence that the value proposition for NHS GM from FDP has materially changed in favour of adoption.” That statement carries weight because the ICB has access to data and analysts who can evaluate such claims.
In contrast, local systems already in use within Greater Manchester have demonstrated their ability to handle analytics tasks. Without clear proof that the national platform outperforms or even matches these existing tools, the case for switching becomes weak. Why adopt a system with known privacy risks when its advantages remain unproven?
Elective Care Backlog and the Real Measure of Success
The elective care backlog in England exceeded 7.6 million appointments by early 2024. Reducing that number requires better coordination, smarter scheduling, and efficient resource allocation. The Federated Data Platform claims to support these goals, but Greater Manchester’s leadership wants to see evidence specific to their region. General promises about improved information flow do not substitute for local data showing faster wait times or better patient outcomes.
One analyst described the situation as “buying a sports car without test driving it” — you might end up with something impressive, but you also might discover it does not suit your roads.
Reason 3: Greater Manchester Already Has Stronger Local Analytics Capabilities
A critical detail often overlooked in the national conversation is that Greater Manchester’s existing data infrastructure is already sophisticated. The ICB stated publicly that its capability in data analytics exceeds what the Federated Data Platform currently offers. That is not a boast; it is a factual comparison drawn from internal evaluations.
A Different Approach to Health Data
Greater Manchester has invested in building its own data integration tools over several years. These systems connect hospitals, GP surgeries, and community health services using architectures that local teams understand and control. When a problem arises, local engineers can fix it without waiting for a contractor based in London or the United States. That autonomy matters for a region managing the health of nearly three million people.
The greater manchester data platform already functions as a homegrown alternative to the national system. It processes data from multiple sources, generates actionable insights for clinicians, and respects the privacy frameworks that local residents expect. Switching to a national platform would mean abandoning this investment and accepting a system that, by the ICB’s own assessment, offers less capability.
Control Over Intellectual Property
Liberal Democrat MP Martin Wrigley raised another troubling point: the NHS, under the current contract, owns none of the software or intellectual property generated by the Federated Data Platform. That means the health service pays a private company to build tools it cannot own, modify, or license to others. In Greater Manchester, locally developed systems remain under public ownership. That distinction matters for long-term sustainability and cost control.
Reason 4: Public Concern Has Only Grown Since the Deferral
When Greater Manchester first deferred its decision on the FDP, the ICB planned to review its position after gathering more information. A Freedom of Information response later revealed that this review is now off the table entirely. Why? Because public concern has heightened, not diminished, since the deferral was announced.
Listening to the Community
Integrated care boards exist to serve their local populations. If residents express strong opposition to a data platform that involves a controversial supplier, the ICB cannot simply ignore those voices. In Greater Manchester, community groups, patient advocates, and local media have all raised alarms about the Palantir deal. Social media campaigns and public meetings have amplified these worries.
One resident described their reaction upon learning about the platform: “I had no idea my hospital data could be shared with a company that works with the CIA. Nobody asked me. Nobody told me. That does not feel like the NHS I trust.” Stories like this accumulate and influence decision-makers.
The Transparency Problem
Public concern thrives when information is scarce. NHS England has not always been forthcoming about the specifics of the Palantir contract, including details about data access policies, security audits, and performance metrics. That lack of transparency feeds suspicion. Even if the platform is entirely safe and beneficial, the perception of secrecy can undermine trust.
You may also enjoy reading: Data Center Guzzled 30 Million Gallons: 5 Unnoticed Signs.
Greater Manchester’s ICB recognized that adopting the FDP without adequately addressing these concerns could damage the relationship between patients and the health system. In healthcare, trust is not a luxury — it is a clinical necessity. Patients who distrust the system may delay seeking care, withhold information from doctors, or opt out of data sharing entirely, which harms research and service planning.
Reason 5: Procurement Controversies and the Risk of Vendor Lock-In
The way the Federated Data Platform was procured continues to attract criticism. The initial £60 million payment to Palantir without competition set a precedent that many procurement experts consider problematic. The subsequent £330 million contract followed a process that some described as “designed for one supplier” rather than a genuinely open competition.
The Break Clause Conversation
Last month, the junior minister responsible for the FDP acknowledged that the government would consider using a break clause to remove Palantir from the contract. That admission is remarkable. It means even officials within the government recognize that the arrangement may need to end early. At the same time, the minister defended the system’s performance, creating a contradictory message that leaves regions like Greater Manchester uncertain about the platform’s longevity.
If the government itself is considering terminating the contract, why would any ICB invest time and resources in integrating with the platform? The risk of adopting a system that might be abandoned mid-deployment is simply too high.
Financial Implications for Local Health Systems
Implementing the Federated Data Platform is not free for ICBs. Even if the central contract covers software costs, local health systems must pay for training, infrastructure adjustments, staff time, and ongoing management. These expenses add up quickly, especially for regions like Greater Manchester that already have working alternatives. Spending money on a system with unclear benefits and uncertain longevity would be difficult to justify to taxpayers and patients.
One health economist estimated that full adoption across a region the size of Greater Manchester could cost several million pounds in transition costs alone. That money could instead fund direct patient care, mental health services, or community health programs.
What This Means for Other Health Regions
Greater Manchester’s stance sends a signal to other ICBs that are evaluating their options. If the largest health region in the North West can decline the FDP and continue operating effectively, others may follow. The greater manchester data platform approach demonstrates that local alternatives exist and can succeed.
Health regions across England now face a choice. They can accept the national platform and hope that its benefits eventually materialize. Or they can invest in local solutions that offer greater control, stronger privacy protections, and clearer ownership of intellectual property. Greater Manchester has chosen the second path, and its reasoning deserves serious consideration.
A Template for Local Innovation
What Greater Manchester has done is not simply rejection — it is constructive independence. The region built its own data analytics infrastructure because the national solution did not meet its needs. Other regions with strong digital health teams could follow the same model. They might partner with academic institutions, local technology companies, or open-source communities to create systems that are transparent, accountable, and tailored to local populations.
The key lesson is that saying no to a national platform does not mean saying no to digital transformation. It means choosing a different, more locally controlled version of that transformation.
The Path Forward for Digital Health in Greater Manchester
The Freedom of Information response made one thing clear: the review of Greater Manchester’s position is not happening. The ICB stands by its decision not to join the FDP, and it will continue to invest in local capabilities. That does not mean the region is closed to collaboration or future national systems, but any future engagement would require fundamental changes in how the FDP is governed, procured, and perceived by the public.
For now, the greater manchester data platform remains under local control. Residents can take some comfort in knowing that their health data is managed by people accountable to the same community. Clinicians continue using tools they understand and trust. And policymakers in other regions have a real-world example of how to approach large-scale health data projects with caution and integrity.
As the national debate over Palantir’s role in the NHS continues, Greater Manchester’s decision looks less like an outlier and more like a preview of what other regions may eventually choose. The questions raised by this case — about privacy, evidence, transparency, and public trust — will not disappear. They are now part of the conversation about what kind of digital health system England wants to build.
